HK1118297A1 - Replication-deficient rna viruses as vaccines - Google Patents

Replication-deficient rna viruses as vaccines

Info

Publication number
HK1118297A1
HK1118297A1 HK08109296.4A HK08109296A HK1118297A1 HK 1118297 A1 HK1118297 A1 HK 1118297A1 HK 08109296 A HK08109296 A HK 08109296A HK 1118297 A1 HK1118297 A1 HK 1118297A1
Authority
HK
Hong Kong
Prior art keywords
cell
iii
dna molecule
genome
replication
Prior art date
Application number
HK08109296.4A
Other languages
English (en)
Inventor
Wolfgang J Neubert
Sascha Bossow
Sabine Schlecht
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of HK1118297A1 publication Critical patent/HK1118297A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08109296.4A 2005-02-11 2008-08-20 Replication-deficient rna viruses as vaccines HK1118297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005006388A DE102005006388A1 (de) 2005-02-11 2005-02-11 Replikationsdefiziente RNA-Viren als Impfstoffe
PCT/EP2006/001251 WO2006084746A1 (de) 2005-02-11 2006-02-10 Replikationsdefiziente rna-viren als impfstoffe

Publications (1)

Publication Number Publication Date
HK1118297A1 true HK1118297A1 (en) 2009-02-06

Family

ID=36353666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109296.4A HK1118297A1 (en) 2005-02-11 2008-08-20 Replication-deficient rna viruses as vaccines

Country Status (23)

Country Link
US (2) US20090041725A1 (zh)
EP (2) EP1851239B1 (zh)
JP (2) JP5679620B2 (zh)
KR (1) KR101279636B1 (zh)
CN (1) CN101155826B (zh)
AT (1) ATE421529T1 (zh)
AU (1) AU2006212385B2 (zh)
BR (1) BRPI0607487A2 (zh)
CA (1) CA2599036C (zh)
DE (2) DE102005006388A1 (zh)
DK (1) DK1851239T3 (zh)
EA (1) EA015013B1 (zh)
ES (1) ES2321651T3 (zh)
HK (1) HK1118297A1 (zh)
HR (1) HRP20090230T1 (zh)
IL (1) IL185147A (zh)
MX (1) MX2007009628A (zh)
PL (1) PL1851239T3 (zh)
PT (1) PT1851239E (zh)
RS (1) RS50977B (zh)
SI (1) SI1851239T1 (zh)
WO (1) WO2006084746A1 (zh)
ZA (1) ZA200707216B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
FI2604695T3 (fi) 2007-12-27 2023-02-16 Replikaatiokyvyttömiä arenavirusvektoreita
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
EP2434012B1 (en) * 2009-05-18 2017-12-13 National Institute of Advanced Industrial Science And Technology Vector material for creating pluripotent stem cells, and pluripotent stem cell creation method using said vector material
US9365866B2 (en) 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
DE102010018961B4 (de) * 2010-04-23 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
ES2640113T3 (es) 2011-02-08 2017-10-31 Mie University Método para producir un vector viral para la transferencia génica
JP6757121B2 (ja) * 2011-10-05 2020-09-16 ジェンヴェック エルエルシー シミアン（ゴリラ）アデノウイルス又はアデノウイルスベクター、及び使用方法
EP2669381A1 (en) * 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
EP2813574B1 (en) * 2013-06-10 2019-02-20 RSV Genius GmbH Semi-live respiratory syncytial virus vaccine
MX367093B (es) * 2013-06-10 2019-08-05 Amvac Ag Vacuna semi-viva del virus sincitial respiratorio.
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
ATE470704T1 (de) * 1995-11-01 2010-06-15 Dnavec Research Inc Rekombinantes sendai-virus
WO2003025570A1 (en) * 2001-09-18 2003-03-27 Dnavec Research Inc. Method of examining (-) strand rna virus vector having lowered ability to form grains and method of constructing the same
CN1347453A (zh) 1999-12-10 2002-05-01 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和病症的用途
JP4791651B2 (ja) * 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
JP2004344001A (ja) * 2003-03-07 2004-12-09 Dnavec Research Inc 胚性幹細胞に遺伝子を導入する方法
JP2004357689A (ja) * 2003-06-03 2004-12-24 Dnavec Research Inc 遺伝子導入ベクターの非侵襲的インビボ評価方法
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe

Also Published As

Publication number Publication date
CN101155826B (zh) 2011-10-12
PT1851239E (pt) 2009-04-28
RS50977B (sr) 2010-10-31
CN101155826A (zh) 2008-04-02
AU2006212385A1 (en) 2006-08-17
EA015013B1 (ru) 2011-04-29
CA2599036C (en) 2014-11-04
KR101279636B1 (ko) 2013-06-28
ZA200707216B (en) 2008-05-28
DK1851239T3 (da) 2009-05-18
JP5679620B2 (ja) 2015-03-04
EA200701695A1 (ru) 2008-02-28
HRP20090230T1 (en) 2009-05-31
EP1851239B1 (de) 2009-01-21
JP2012213407A (ja) 2012-11-08
CA2599036A1 (en) 2006-08-17
BRPI0607487A2 (pt) 2009-09-08
ES2321651T3 (es) 2009-06-09
AU2006212385B2 (en) 2011-12-15
US20180142256A1 (en) 2018-05-24
US11028409B2 (en) 2021-06-08
PL1851239T3 (pl) 2009-07-31
KR20070110345A (ko) 2007-11-16
US20090041725A1 (en) 2009-02-12
MX2007009628A (es) 2007-11-15
DE502006002711D1 (de) 2009-03-12
WO2006084746A1 (de) 2006-08-17
EP2045260A1 (de) 2009-04-08
SI1851239T1 (sl) 2009-08-31
IL185147A0 (en) 2007-12-03
EP1851239A1 (de) 2007-11-07
ATE421529T1 (de) 2009-02-15
IL185147A (en) 2011-12-29
DE102005006388A1 (de) 2006-08-24
JP2008529508A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
IL185147A0 (en) Replication-deficient rna viruses as vaccines
EP1747023B1 (en) Methods and compositions for reducing hcv viral genome amounts in a target cell
Varnavski et al. Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors
Kneidinger et al. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery
Kim et al. Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus
GB201103167D0 (en) Gene silencing
Rothe et al. Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30
Kayhan et al. Inhibition of hepatitis B virus replication by shRNAs in stably HBV expressed HEPG2 2.2. 15 cell lines
Peng et al. shRNA driven by Pol II/T7 dual-promoter system effectively induce cell-specific RNA interference in mammalian cells
WO2007149946A3 (en) Composition and methods for expressing reporter molecules in mammalian cells
US8957199B2 (en) Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
Hinzman et al. Selection for gene junction sequences important for VSV transcription
de Carvalho et al. Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus
JP2017000015A (ja) 目的遺伝子の発現誘導可能なウイルスベクター
EP2485745B1 (en) A composition for creating conditional lethality of virus mutants and for eliminating the viability of an eukaryotic cell
JP2004305140A (ja) Ｃ型肝炎ウイルスのタンパク質合成及び／又はｃ型肝炎ウイルスの複製を抑制することができる二本鎖オリゴヌクレオチド
AU2015201136B2 (en) Methods and compositions for reducing viral genome amounts in a target cell
CN115667524A (zh) 病毒载体生产
TW200714713A (en) A virus vector for inducing gene inactivation of plants
US20170226550A1 (en) Inhibitory rna for enhanced protein production in recombinant mammalian cells
Scott Inhibition of Rift Valley Fever Virus Using RNA Interference Technology

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200214